CONSORTIUM HIGHLIGHT: NUR LATIFAH HANUM

Meet Nur Latifah Hanum, Clinical Research Site Specialist at INA-RESPOND, Indonesia

Since joining INA-RESPOND in 2020, Nur Latifah Hanum has emerged as a vital force in advancing clinical research across Indonesia. With a Bachelor’s degree in Community Nutrition and over a decade of experience in clinical and observational research, Hanum brings both expertise and dedication to her role as Clinical Research Site Specialist.

A Comprehensive Approach to Clinical Research

In her current position, Hanum oversees the complete lifecycle of clinical research activities—from study startup to closeout. Her responsibilities span a wide range of critical functions, including training and mentoring hospital staff, coordinating site activation, monitoring quality standards, and ensuring adherence to Good Clinical Practice (GCP) guidelines. She also manages complex regulatory processes, including investigational product importation and Material Transfer Agreements (MTA).

As a key liaison between principal investigators, site personnel, and the INA-RESPOND Operations Center, Hanum has contributed to groundbreaking studies involving HIV, tuberculosis, and COVID-19 research.

Making an Impact: Key Study Contributions

Hanum’s work has been instrumental in several significant research initiatives:

TRIPOD Study (2020): As part of the RePORT TB Cohort A in Indonesia, Hanum played a crucial role in coordinating this multi-site study across seven hospitals, utilizing the OpenClinica Clinical Data Management System to facilitate collaboration and data sharing.

Epidemiologic Research: She contributed to the Epi Protocol study examining “Epidemiologic Factors Associated with Tuberculosis Treatment Outcomes Across RePORT International Consortia.”

TB Biomarker Study: Hanum provided critical support for cross-site collaboration in analyzing host biomarkers associated with adverse TB treatment outcomes, leading coordination of Material Transfer Agreements across international sites.

Embracing Technological Evolution

Hanum’s role has evolved significantly with advancing technologies and research methodologies. She has successfully adapted to digital systems including electronic data capture (EDC) and online platforms, which have enhanced research efficiency and data quality while reducing delays.

“These technologies have allowed us to monitor study progress in real time, improve data quality, and reduce delays,” Hanum explains. During the COVID-19 pandemic, she quickly pivoted to virtual training delivery, ensuring continued support for site staff despite challenging circumstances.

Her expanded responsibilities now include quality management, advanced staff training, regulatory processes, and helping sites adopt cutting-edge research practices—a evolution that has enhanced her professional growth and study success.

Vision for the Future

Looking ahead, Hanum envisions a future where TB research becomes increasingly integrated with technological advancements. She believes digital tools will enable faster, more accurate data collection and analysis, while global consortia collaboration will facilitate seamless information exchange.

“I am confident that future research will focus more on developing personalized treatments tailored to the unique needs of each patient,” she shares. “With the support of increasingly advanced technology and strong collaboration with global consortia, we can elevate the quality of TB research and discover more effective solutions in the fight against tuberculosis.”

Recognizing Excellence

Hanum’s dedication to advancing TB research through technology, collaboration, and mentorship exemplifies the spirit of our consortium. Her ability to bridge traditional research practices with innovative methodologies positions her as a leader in the next generation of clinical research specialists.

Through her work at INA-RESPOND, Hanum continues to contribute to the global fight against tuberculosis, ensuring that research advances translate into better outcomes for patients worldwide.